ERYTHROMYCIN LACTOBIONATE (erythromycin lactobionate) by Pfizer is mechanism of action erythromycin acts by inhibition of protein synthesis by binding 50 s ribosomal subunits of susceptible organisms. Approved for penicillin-allergic patients, the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, the severity of the infection requires immediate high serum levels of erythromycin. First approved in 2022.
Drug data last refreshed 22h ago
Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis.
Worked on ERYTHROMYCIN LACTOBIONATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.